Invitrogen reagents among those to be used in kits for Solexa Genome Analysis System 

Carlsbad, Calif., and Hayward, Calif. and Cambridge, UK-- June 13, 2006—Invitrogen Corporation (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery, and Solexa, Inc. (Nasdaq: SLXA), a provider of next-generation genetic analysis systems, today announced a collaboration through which Invitrogen will supply many of the reagents for Solexa’s sequencing, gene expression, and small RNA analysis kits designed to be used with the Solexa Genome Analysis System.  Financial terms of the collaboration were not disclosed. 

With the potential to generate over a billion bases of DNA sequence data per run, Solexa expects the Solexa Genome Analysis System to reduce the cost and improve the speed of a broad range of applications, including whole genome human sequencing and expression profiling. Solexa’s platform, which leverages the company’s proprietary Clonal Single Molecule Array™ technology and reversible-terminator chemistry, has the versatility and scalability to address researchers’ needs in a range of settings, including core facilities, genome centers, and individual laboratories. Solexa is currently taking orders for the system and expects to commence broad shipment of the technology platform in fall 2006.  

“As Solexa advances along the path to broadly commercialize our genetic analysis platform with the goal of enabling customers to re-sequence human genomes for $100,000, we are committed to working with leading companies in the life science business,” said John West, chief executive officer of Solexa.  “Our customers want the best reagents to use on our platforms, and with Invitrogen’s well-earned reputation for manufacturing and delivering consistently high quality reagents, we are confident that our customers’ expectations will be met.” 

In addition to its role as a manufacturer of key life science products, Invitrogen also serves in an original equipment manufacturer (OEM) capacity in the diagnostic and life sciences reagent markets, providing technologies for a wide range of areas.  Raw materials such as enzymes, antibodies, fluorescent labeling molecules and magnetic beads for bioseparations are incorporated into commercial products from various suppliers that are being used in leading clinical and research labs today. 

“Our relationship with Solexa will allow us to be a significant player in an area that could change the shape of human medicine,” said Claude Benchimol, Invitrogen’s Senior Vice President, Research and Development. “Furthermore, by supplying the majority of reagents in these Solexa-branded kits, we continue to demonstrate our leadership role as an OEM supplier.  With our flexibility, manufacturing capability and breadth of raw materials, we can readily handle a variety of kits for our manufacturing partners such as the ones that are needed to run on Solexa’s platform.” 

ENDS 

About Invitrogen

Invitrogen provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of approximately $1.2 billion in 2005. For more information, visit www.invitrogen.com .

About Solexa

Solexa, Inc. is developing and preparing to commercialize the Solexa Genome Analysis System, which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and small-RNA analysis. Solexa expects its first-generation instrument to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human re-sequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. For further information, please visit www.solexa.com . 

This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development, commercialization of the Company’s novel genetic analysis technology, and the expansion and success of Solexa's commercial application of its genomics technologies.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006.  Solexa does not undertake any obligation to update forward-looking statements.  

For more information, please contact:  

Invitrogen Contacts:                                                                Solexa Contact:

Media Contacts:                                                                      Company:

Eric Endicott                                                                           Linda Rubinstein, VP & CFO

Invitrogen Corporation                                                             (510) 670-9300

(760) 268 7438

Eric.endicott@invitrogen.com                                                Investor Relations:

or                                                                                             Lippert/Heilshorn & Associates

Greg Geissman                                                                      Jody Cain/Mariann Ohanesian

Invitrogen Corporation                                                             (310) 691-7100

(760) 476-7032

gregory.geissman@invitrogen.com                                        European Media

                                                                                                Northbank Communications

                                                                                                Sue Charles, CEO     

                                                                                                +44 (0)20 7886 8152